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ABSTRACT	 	A	simple,	rapid,	precise	and	accurate	method	is	developed	for	the	quantitative	simultaneous	determination	of	ceftriaxone	and	tazobactum	in	bulk	and	pharmaceutical	formulations.	Separation	of	ceftriaxone	and	tazo-bactum	was	successfully	achieved	by	using	Inertsil	C18	ODS	column	250X4.6mm,	5µm	in	an	isocratic	mode	using	water	and	acetonitrile	(80:20)	at	a	flow	rate	of	1.0	ml/min	and	was	monitored	at	254	nm	with	a	re-tention	time	of	3.049	minutes	and	4.317	minutes	for	ceftriaxone	and	tazobactum	respectively.	The	method	was	validated	and	the	response	was	found	to	be	linear	in	the	drug	concentration	range	of	20µg/ml	to	80	µg/ml	for	ceftriaxone	and	5	µg/ml	to	35	µg/ml	for	tazobactum.	The	values	of	the	correlation	coefficient	were	found	to	be	0.999	for	ceftriaxone	and	0.999	for	tazobactum	respectively.	The	LOD	and	LOQ	for	ceftriaxone	were	found	to	be	0.021	and	0.064	respectively.	The	LOD	and	LOQ	for	tazobactum	were	found	to	be	0.030	and	0.091	respectively.	The	percentage	recovery	for	ceftriaxone	and	tazobactum	were	found	to	be	98-102%	respectively	which	 indicates	 that	 the	proposed	method	 is	highly	accurate.	The	specificity	of	 the	method	shows	good	correlation	between	retention	times	of	standard	with	the	sample.	The	method	was	extensively	validated	according	to	ICH	guidelines	for	Linearity,	Accuracy,	Precision,	Specificity	and	Robustness.		Stability	of	the	drugs	was	determined	by	using	acid/base,	thermal,	oxidative	stress	testing.	
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INTRODUCTION	Analytical	method	development	and	validation	places	an	important	role	in	drug	discovery	and	manufacture	
of	pharmaceuticals[1].	Development	of	simple	and	re-producible	analytical	methods	for	estimation	of	multi	component	 drugs	 is	 very	 important	 part	 of	 quality	control	and	for	social	awareness	which	is	established	in	present	work[2].	Ceftriaxone[3]	 is	 a	 beta-lactum	 third	 generation	broad-spectrum	 cephalosporin	 antibiotic.	Ceftriaxone	 works	 by	 inhibiting	 the	 mucopeptide	synthesis	 in	 the	bacterial	 cell	wall.	The	beta-lactam	moiety	 of	 Ceftriaxone	 binds	 to	 carboxypeptidases,	endopeptidases	and	transpeptidases	in	the	bacterial	cytoplasmic	membrane.	
 
Figure 1: Ceftriaxone and Tazobactum	Tazobactum[4]	broadens	the	spectrum	of	piperacillin	by	making	it	effective	against	organisms	that	express	beta-lactamase	 and	 would	 normally	 degrade	
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piperacillin.	 Tazobactum	 is	 a	 compound	 which	inhibits	 the	action	of	bacterial	beta-lactamases.	 It	 is	added	 to	 the	 extended	 spectrum	 beta-lactam	antibiotic	piperacillin.	
MATERIALS	AND	METHODS	
Chemicals	and	Reagents:	Ceftriaxone	and	Tazobac-tum	were	kindly	gifted	by	Nutech	Biosciences	Pvt	Ltd,	Hyderabad	certified	to	contain	99.8%	and	99.9%	pu-rity	 respectively.	The	drugs	were	used	without	 fur-ther	 purification.	 All	 the	 solvents	 used	 in	 analysis	were	 of	 HPLC	 grade.	 Tazox	 injections	 (label	 claim	1000	mg	of	Ceftriaxone	and	125	mg	Tazobactum)	was	used	in	analysis.	
HPLC	Method	
Instrument:	LC	system	used	consists	of	Waters	2690	pump	model	with	universal	loop	injector	of	injection	capacity	20	μL.	Detector	consists	of	dual	wavelength	photo	diode	detector.	The	column	used	was	Inertsil	C18	Column,	5μ	(250×	4.6	mm)	at	ambient	tempera-ture.	Different	mobile	phases	were	tested	in	order	to	find	the	best	conditions,	for	separating	both	the	drugs	simultaneously.	
 
Figure 2: Chromatogram of Standard solution of 
ceftriaxone and Tazobactum 
 
Figure 3: Chromatogram of Sample solution of ceftri-
axone and Tazobactum 
Optimized	Chromatographic	conditions:	The	mo-bile	 phase	 consisting	 of	 Water:	 Acetonitrile	 (80:20	v/v)	was	selected	because	it	was	found	that	it	ideally	resolve	the	peaks	with	retention	time	(RT)	3.04	min	and	4.31	min	for	Ceftriaxone	and	Tazobactum	respec-tively.	 Wavelength	 was	 selected	 by	 scanning	 all	standard	 drugs	 over	 a	 wide	 range	 of	 wavelength	200nm	to	350nm.	Both	the	components	showed	rea-sonably	good	response	at	254	nm.	
Standard	Preparation:	Weigh	accurately	and	trans-fer	10	mg	of	ceftriaxone	and	1.25	mg	of	tazobactum	in	a	10ml	volumetric	flask,	dissolved	with	5ml	of	mo-bile	phase	and	sonicate	for	10	min	and	finally	made	up	the	volume	with	the	mobile	phase.	From	this	solu-tion	0.4	ml	was	transferred	in	a	10	ml	volumetric	flask	and	the	volume	was	made	up	with	the	mobile	phase	to	get	40	ug/ml	solution	of	ceftriaxone	and	5	ug/ml	solution	 of	 Tazobactum.	 This	 solution	 was	 filtered	through	a	0.45	um	filter	before	use.	
Sample	Preparation:	Accurately	weighed	56.25	mg	(eq.wt)	of	sample	was	transferred	to	a	10	ml	volumet-ric	 flask,	 dissolved	 with	 5	 ml	 of	 mobile	 phase	 and	sonicated	for	10	min	and	finally	made	up	the	volume	with	 the	 mobile	 phase.	 The	 solution	 was	 filtered	through	a	Whatman	filter	paper	and	from	the	filtrate,	0.4	ml	was	transferred	in	a	10	ml	volumetric	flask	and	the	volume	was	made	up	with	the	mobile	phase.	This	solution	was	 filtered	again	 through	a	0.45	um	 filter	before	use.	
Recovery	studies:	To	check	the	accuracy	of	sample	by	the	developed	methods	and	to	study	the	interfer-ence	of	formulation	additives,	analytical	recovery	ex-periments	 were	 carried	 out	 by	 standard	 addition	method	 at	 80,	 100	 and	 120%	 level.	 From	 the	 total	amount	of	drug	found,	the	percentage	recovery	was	calculated.	The	results	are	reported	in	Table	1.	
Analysis	data	of	Capsule	formulations	
Table 1: Analysis data of Capsule formulations 
Parameter	 Hplc	Ceftriaxone	 Tazobactum	Label	claim(mg)	 1000	 125	Drug	found	 1002.7	 125.4	%	Accuracy	 99-101	 99-101	%	Recovery±RSD	 100.27±0.45	 100.38±0.36	
RESULTS	AND	DISCUSSION	 	
Preparation	of	 Calibration	Curves	by	HPLC:	 In	 a	series	of	10	ml	volumetric	 flask	several	dilutions	of	Ceftriaxone	 (20-80μg/ml)	 and	 Tazobactum	 (5-35	μg/ml)	were	prepared	using	mobile	phase	as	solvent.	Each	solution	was	injected	into	HPLC	system	and	the	chromatograms	 were	 recorded.	 The	 peak	 areas	 of	both	drugs	were	 calculated	and	 the	 respective	 cali-bration	curves	were	plotted	against	ratio	of	area	un-der	curve	and	concentration	of	drug.	The	equations	of	the	regression	lines	obtained	are	for	Ceftriaxone:	R²	=	0.999	For	Tazobactum:	R²	=	0.998	
HPLC	Method	Validation:	As	per	the	ICH	guidelines,	the	method	validation	parameters	checked	were	lin-earity,	accuracy,	Specificity,	precision,	limit	of	detec-tion,	limit	of	quantitation.	
Linearity:	A	Series	of	 solutions	 are	prepared	using	Ceftriaxone	 and	 Tazobactum	 working	 standards	 at	concentration	 levels	 from	 20ppm	 to	 80ppm	 of	
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ceftriaxone	 and	 5ppm	 to	 35ppm	 of	 tazobactum	 of	target	concentration.	Inject	into	the	chromatographic	system	and	Measure	the	peak	area.	
 
Figure 4: Linearity Curve of Ceftriaxone	
 
Figure 5: Linearity Curve of Ceftriaxone	Plot	a	graph	of	peak	area	versus	concentration	(on	X-axis	 concentration	 and	 on	 Y-axis	 Peak	 area)	 and	calculate	the	correlation	coefficient.					
Precision:	 Precision	 of	 the	 analytical	 method	 was	studied	by	analysis	of	multiple	sampling	of	homoge-neous	 sample.	 Precision	 was	 demonstrated	 by	 re-peatability	 and	 intermediate	 precision	 measure-ments	of	peak	area	and	peak	symmetry	parameters	of	HPLC	method	for	each	title	ingredients.	The	repeata-bility	 (within-day	 in	 triplicates)	 and	 intermediate	precision	(for	2	days)	were	carried	out	at	five	concen-tration	 levels	 for	 each	 compound.	 Triplicate	 injec-tions	were	made	and	the	obtained	results	within	and	between	the	days	of	trials	were	in	acceptable	range.	The	value	of	%RSD	for	Ceftriaxone	and	Tazobactum	were	found	to	be	less	than	2	indicates	that	the	devel-oped	method	is	precise.	
Accuracy:	Accuracy	 of	 an	 analytical	 method	 is	 the	closeness	of	test	results	obtained	by	that	method	to	the	true	value.	The	accuracy	of	an	analytical	method	should	be	established	across	its	linearity	range.	Accu-racy	 was	 performed	 in	 three	 different	 levels,	 each	level	in	triplicate	for	Ceftriaxone	and	Tazobactum	us-ing	standards	at	80%,	100%	and	120%.	Each	sample	was	analysed	in	triplicate	for	each	level.	The	mean	re-coveries	were	found	in	the	range	of	98	–	102	%,	by	which	we	can	say	the	method	was	accurate.	
limit	of	detection	(LOD)	and	limit	of	quantitation	
(LOQ):	It	is	calculated	according	to	ICH	recommenda-tions	where	 the	 approach	 is	 based	 on	 the	 signal	 to	noise	 ratio.	 Chromatogram	 signals	 obtained	 with	known	 low	 concentrations	 of	 analytes	 were	 com-pared	with	the	signals	of	blank	samples.	A	signal-to-
noise	ratio	3:1	and	10:1	was	considered	for	calculat-ing	LOD	and	LOQ	respectively.	
Table 2: Validation Parameters 
Validation	
Parameters	
HPLC	
Ceftriaxon
e	
Tazobactu
m	Calibration	Range	(μg	mL-1	)	 20-80	 5-35	Linearity	Coefficient	(R2)	 0.999	 0.999	
Precision	(%RSD)	
Inter	Day	 0.021	 0.009	Intra	Day	 0.018	 0.023	LOD	 0.021	 0.030	LOQ	 0.064	 0.091	Tailing	Factor	 1.146	 1.096	Theoretical	Plates	 10038	 8358	
Specifity:	Volume	of	20	μL	of	working	placebo	sam-ple	solution	was	injected	into	the	chromatograph	and	the	chromatogram	was	recorded	and	presented	be-low.	
 
Figure 6: Chromatogram of Blank 
 
Figure 7: Chromatogram of Sample 
Forced	degradation	(stability)	
Acid/	Base	Stress	Testing:	Acid/Base	stress	testing	is	 performed	 to	 force	 the	 degradation	 of	 a	 drug	substance	 to	 its	 primary	 degradation	 products	 by	exposure	 to	 acidic	 and	 basic	 conditions	 over	 time.	Acid	 testing	 was	 done	 by	 taking	 samples	 and	 was	treated	 separately	with	 5.0ml	 of	 1.0N	Hydrochloric	acid	 and	 kept	 on	 bench	 top	 for	 10	 minutes.	 The	treated	sample	was	analysed	and	tabulated.	For	base	degradation	 study,	 sample	 was	 treated	 separately	
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with	 5ml	 of	 0.05N	 Sodium	 hydroxide	 and	 kept	 on	bench	top	for	5	minutes.		
Thermal	 Stress	Testing:	The	 thermal	 stress	 study	was	carried	out	with	the	sample	solution	at	80°C	for	12	 hours.	 Then	 the	 sample	 was	 screened	 for	degradation	 products	 by	 the	 developed	 HPLC	method.		
Oxidative	 Stress	 Testing:	 Oxidative	 studies	 were	performed	by	taking	H2O2;	tablets	sample	was	treated	separately	with	5ml	of	3.0%v/v	solution	of	hydrogen	peroxide	and	kept	on	bench	top	for	60	minutes.		
Table 3: Forced Degradation for Ceftriaxone and Tazo-
bactum 
Mode	of	
degradation	
%	degradation	
Ceftriaxone	 Tazobactum	Acid	 0.23	 1.21	Base	 0.46	 0.08	Oxidative	 0.8	 0.11	Thermal	 0.79	 1.08	
CONCLUSION	The	methods	described	for	simultaneous	estimation	of	Ceftriaxone	and	Tazobactum	are	found	to	be	sim-ple,	 sensitive,	accurate,	precise,	 rapid	and	economi-cal.	Hence	method	could	be	successfully	employed	for	routine	 analysis	 of	 Ceftriaxone	 and	 Tazobactum	 in	their	combined	dosage	form.	
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